51 completed, 12 terminated, 1 withdrawn. 40 Phase 1, 31 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 40 | Completed 30, Terminated 9, Withdrawn 1 |
| Phase 2 | 31 | Completed 25, Terminated 5, Withdrawn 1 |
Follow alvocidib: new trials by email Literature Review of alvocidib trials Research Report on alvocidib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML Alvocidib Hydrochloride, Decitabine, Venetoclax - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2020-10-01 | 2020-11-12 | |
| Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy Alvocidib (flavopiridol) and cytarabine (Ara-C), Alvocidib (flavopiridol) - Acute Myeloid Leukemia (AML) | Phase 2 | Terminated | Sumitomo Pharma America, Inc. | 11 | 2020-01-15 | 2023-11-09 |
| A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine - Myelodysplastic Syndromes (MDS) | Phase 1 / Phase 2 | Terminated | Sumitomo Pharma America, Inc. | 20 | 2018-08-29 | 2023-11-09 |
| A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Venetoclax, Alvocidib - Acute Myeloid Leukemia (AML) | Phase 1 | Completed | AbbVie | 36 | 2018-05-30 | 2022-02-01 |
| A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia Alvocidib, Cytarabine, Mitoxantrone - Acute Myeloid Leukemia | Phase 1 | Completed | Sumitomo Pharma Co., Ltd. | 10 | 2018-05-15 | 2022-04-12 |
| Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML). Alvocidib, Cytarabine, Daunorubicin - Acute Myeloid Leukemia | Phase 1 | Completed | Sumitomo Pharma America, Inc. | 32 | 2017-09-25 | 2023-11-15 |
| Alvocidib Biomarker-driven Phase 2 AML Study Alvocidib, Cytarabine, Mitoxantrone - Acute Myeloid Leukemia | Phase 2 | Terminated | Sumitomo Pharma America, Inc. | 104 | 2016-03-14 | 2023-11-15 |
| Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia alvocidib, daunorubicin hydrochloride, mitoxantrone hydrochloride - Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 2 | Completed | National Cancer Institute (NCI) | 172 | 2011-04-01 | 2017-07-31 |
| Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Alvocidib Hydrochloride, Cyclophosphamide, Diagnostic Laboratory Biomarker Analysis - Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 9 | 2010-04-01 | 2015-11-11 |
| Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery alvocidib, irinotecan hydrochloride, laboratory biomarker analysis - Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach | Phase 2 | Completed | National Cancer Institute (NCI) | 19 | 2009-09-01 | 2014-05-26 |
| Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors Alvocidib Hydrochloride, Fluorouracil, Leucovorin Calcium - Recurrent Extragonadal Seminoma, Recurrent Malignant Extragonadal Germ Cell Tumor | Phase 2 | Completed | National Cancer Institute (NCI) | 36 | 2009-06-01 | 2017-03-10 |
| Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia alvocidib, mitoxantrone hydrochloride, cytarabine - Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7) | Phase 2 | Completed | National Cancer Institute (NCI) | 78 | 2008-11-01 | 2018-08-07 |
| Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia alvocidib, mitoxantrone hydrochloride, carboplatin - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 2 | Completed | National Cancer Institute (NCI) | 92 | 2008-10-01 | 2015-07-07 |
| Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Alvocidib Hydrochloride, Lenalidomide, Pharmacological Study - Anemia, Chronic Lymphocytic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 39 | 2008-08-01 | 2015-04-02 |
| Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia alvocidib, cytarabine, mitoxantrone hydrochloride - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 1 | Completed | National Cancer Institute (NCI) | 35 | 2007-04-01 | 2013-09-30 |
| Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL) alvocidib - Leukemia, Lymphocytic, Chronic | Phase 2 | Completed | Sanofi | 165 | 2007-03-01 | 2013-02-12 |
| Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma Flavopiridol - Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 28 | 2006-11-27 | 2018-01-30 |
| Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia alvocidib, cytarabine, mitoxantrone hydrochloride - Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 45 | 2006-10-01 | 2015-08-04 |
| Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma alvocidib, pharmacological study, laboratory biomarker analysis - B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Small Lymphocytic Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 24 | 2006-09-01 | 2013-07-02 |
| Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors alvocidib, vorinostat, pharmacological study - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | National Cancer Institute (NCI) | 60 | 2006-03-01 | 2014-02-24 |
Showing 20 of 64. Sign in to see all of them.
Leukemia, Myeloid, Acute (15) · Leukemia, Lymphocytic, Chronic, B-Cell (10) · Congenital Abnormalities (7) · Lymphoma, Mantle-Cell (7) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Leukemia, Erythroblastic, Acute (6) · Leukemia, Monocytic, Acute (6) · Leukemia, Myelomonocytic, Acute (6) · Leukemia, Megakaryoblastic, Acute (5) · Lymphoma, Follicular (5) · Lymphoma, Large B-Cell, Diffuse (5) · Lymphoma (4) · Lymphoma, B-Cell, Marginal Zone (4) · Lymphoma, Non-Hodgkin (4) · Waldenstrom Macroglobulinemia (4)
National Cancer Institute (NCI) (43) · Memorial Sloan Kettering Cancer Center (5) · Sumitomo Pharma America, Inc. (4) · NCIC Clinical Trials Group (3) · AbbVie (1) · Barbara Ann Karmanos Cancer Institute (1) · Gynecologic Oncology Group (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · SWOG Cancer Research Network (1) · Sanofi (1) · Sumitomo Pharma Co., Ltd. (1) · Virginia Commonwealth University (1)
United States (61) · Canada (5) · United Kingdom (4) · Australia (2) · Germany (2) · Belgium (1) · France (1) · Israel (1) · Italy (1) · Japan (1) · Netherlands (1) · Norway (1) · Puerto Rico (1) · Spain (1)
Gary K. Schwartz, MD (5) · John Byrd (4) · Judith Karp (4) · Stephen Anthony, DO (4) · Gary K. Schwartz (2) · Gary Schwartz (2) · Geoffrey Shapiro (2) · Keith Bible (2) · Steven Grant (2) · Angela Dispenzieri (1) · Antoinette R. Tan, MD (1) · B. Smith (1) · Barbara A. Conley, MD (1)
PMID 19826119, PMID 22289993, PMID 24990615, PMID 12735303, PMID 14871968, PMID 15122079, PMID 15791454, PMID 15978659, PMID 16683073, PMID 17251659, PMID 20460644, PMID 21072184, PMID 21239698, PMID 22664059, PMID 22733022, PMID 24241210, PMID 25596730, PMID 26022709, PMID 26819054, PMID 27118540, PMID 32998965, PMID 35689544
U01CA076576 (8), U01CA069856 (7), P30CA016058 (5), U01CA070095 (5), U01CA062490 (4), P30CA006973 (3), P30CA008748 (3), R01CA067819 (3), N01CM00100 (2), P30CA006516 (2), P30CA015083 (2), U01CA062491 (2), U01CA069912 (2), 2017 (1), N01CM00038 (1)